Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Survey for People Diagnosed with Breast Cancer to Provide Feedback on a New Type of Clinical Trial
Glossary on
off
Printer Friendly Page Survey for People Diagnosed with Breast Cancer to Provide Feedback on a New Type of Clinical Trial

Survey for People Diagnosed with Breast Cancer to Provide Feedback on a New Type of Clinical Trial

Surveys, Registries, Interviews
Survey for people diagnosed with stage 0 - stage 3 breast cancer

Study Contact Information:

Divya Parikh, MD, Stanford University of Medicine: 650-723-4000, pager 13699


Survey for People Diagnosed with Breast Cancer to Provide Feedback on a New Type of Clinical Trial

About the Study

Stanford researchers invite people diagnosed with 0 to 3 breast cancer to take this 15 minute survey to share your thoughts about the advantages and disadvantages of participating in a new type of clinical trial called “a window opportunity” trial. Researchers will use this information to help design future clinical trials. Click here to take the survey.

What the Study Involves

When you participate in this survey:

  • You will be provided a definition of a “window of opportunity” clinical trial and be asked to fill out a survey to gather your views on participation in this type of clinical trial.
  • This survey asks questions about your breast cancer diagnosis, cancer and treatment you may have received.
  • Survey responses will be recorded in a database on a secure Stanford encrypted computer with removal of any identifying information about you.

Lead Researchers

Jennifer Caswell-Jin, MD, Stanford University of Medicine
Divya Parikh, MD, Stanford University of Medicine: 650-723-4000, pager 13699

 

 

This Study is Open To:

People can participate if they are:

  • age 18 or older
  • have had a diagnosis of 0, 1, 2, or 3 breast cancer

 

This Study is Not Open To:

People with the following are not eligible:

  • 4 breast cancer at diagnosis (recurrent breast cancer is eligible)